Michael Sweet
.webp)
After months or years of R&D and design refinement, your medical device or drug delivery system is ready for the next critical milestone: Good Laboratory Practice (GLP) preclinical studies conducted under 21 CFR Part 58. Or is it?
Every year, medical device and pharmaceutical innovators (from ambitious startups to established companies) rush into GLP studies before they're truly ready. The result? Wasted time, burned budgets, repeat studies, and regulatory setbacks that can delay market entry by months or years.
GLP studies aren't practice runs or “dress rehearsals” for clinical trials. They're regulatory submissions in the making. When you initiate a GLP study, you're generating data that must withstand regulatory (FDA or other notified body) scrutiny, data that could make or break your device's pathway to commercialization.
How do you know you’re ready for GLP preclinical work? The easier way to understand that is by identifying how you know you are not.
Here are five critical indicators that you're not ready for GLP preclinical studies.
If any of these apply to your program, you may need to pause and reassess before moving forward.
1. Your Device Design Isn't Locked
You're not ready for a GLP study if: Your device is still evolving, even in seemingly minor ways.
This is the most common readiness gap we see. Sponsors come to us saying, "We're still working on the handle," or "We're optimizing the software," or "We're finalizing the coating formulation." These aren't small details. They can be deal-breakers.
When you conduct a GLP study, regulatory bodies are approving that specific iteration of your device. Under 21 CFR Part 58, the test article must be clinically equivalent to what you'll ultimately submit. Any change (to design specifications, manufacturing processes, packaging, sterilization methods, or material characterization) could require a new submission and send you back to square one.
A true design lock goes beyond freezing your initial engineering drawings. It requires complete and traceable documentation, much of which becomes part of the GLP Final Report:
-
Final device specifications and dimensions
-
Manufacturing processes and quality controls
-
Packaging and sterilization methods
-
Material characterization and biocompatibility data
-
Instructions for use
If you’re viewing your GLP study as a chance to validate design tweaks, you’re not ready. Those refinements belong in pilot, feasibility, or non-GLP work — not in a regulatory submission intended to demonstrate safety and performance.
2. Choose Your GLP Partner Like Your Submission Depends On It
You're not ready if: You haven’t thoughtfully identified and vetted a preclinical CRO with the expertise, compliance infrastructure, and capabilities your program requires.
Choosing a preclinical contract research organization based primarily on cost is one of the most expensive mistakes you can make. The cheapest option can often lead to the costliest outcome: failed studies, regulatory questions, or complete do-overs at another facility.
Before committing to a GLP study, ensure your selected lab has:
-
Proven GLP compliance: Ask how many GLP-compliant studies they've completed and how many have resulted in regulatory submissions. Request details about their most recent FDA inspections, Form 483 observations, and corrective actions.
-
Independent Quality Assurance Unit (QAU): This isn't optional. It's required under 21 CFR Part 58.
-
Study Directors with deep regulatory fluency: You need professionals who understand not just GLP regulations, but in medical-device regulatory pathways such as 510(k), IDE, and PMA. Their interpretation of the data and meeting compliance standards determines how smoothly your submission process goes.
-
Appropriate facilities and equipment: Verify they have the space, surgical environments, imaging capabilities, and validated equipment your study requires, and that these resources will be available on your timeline.
-
Therapeutic area expertise: Experience with your device category matters. You don't want to fund someone else's learning curve.
If you haven't audited your potential CRO partner or confirmed their capabilities and facilities align with your study needs, you're not ready.
3. You Don't Have the Appropriate Budget and Timeline
You're not ready if: You're hoping to complete a GLP study in less than six months or haven't secured adequate funding.
One of the most persistent misconceptions about GLP preclinical studies is that they can be rushed. They cannot.
A realistic timeline from study initiation to final signed report is typically 6 to 12 months, and that's assuming everything proceeds smoothly. The reporting phase alone (including histopathology processing, data analysis, and documentation) requires 12 to 16 weeks minimum. Certain processes, like plastic resin embedding for histology, have hard timelines that no amount of money can compress.
Budget considerations are equally critical. GLP studies require significant investment:
- Smaller studies: ~$250,000
- Medium-complexity studies: ~$500,000
- Larger or complex studies: $1,000,000+
If your planning revolves around an executive deadline (“We need submission by December”) rather than scientific and regulatory readiness or if your CRO selection is driven by the lowest quote, you are setting your program up for delays and costly do-overs.
A well-planned GLP study requires appropriate resources, realistic expectations of timelines and disciplined project management. When those align, timelines hold and data quality stands up to regulatory scrutiny.
4. You're Not Ready for the Documentation Burden
You're not ready if: Your company lacks the infrastructure to handle the regulatory and manufacturing documentation that accompanies GLP studies.
Here's what many innovators don't realize: the CRO generates the GLP [final] report, but you own the regulatory submission. More importantly, once that data is submitted to the FDA, your entire documentation trail becomes fair game for audits.
Ask yourself:
- Do you have in-house regulatory expertise or qualified regulatory consultants?
- Can you maintain meticulous manufacturing records indefinitely?
- Is your quality management system (QMS) ready for an FDA audit?
- Do you have data archiving and retrieval protocols in place?
If you're a five-person engineering team with no one who's ever submitted to a regulatory body, you need help before initiating GLP studies. People underestimate how strictly compliant GLP is supposed to be. This isn't an academic environment. It's a regulated process where every deviation, every protocol change, every piece of data must be documented and defensible.
Your house must be in order before you invite regulatory scrutiny.
5. You Haven't Completed At Least One Pilot Study
You're not ready if: You're jumping straight to GLP studies without pilot or non-GLP feasibility work to confirm your model and refine your protocol.
Pilot studies aren't optional preliminaries. They're your best insurance against costly GLP failures. Even the most comprehensive study design and protocol can fail under real preclinical conditions. Until you’ve tested your device in a relevant preclinical model, you’re still in the assumption phase.
Non-GLP pilot studies accomplish several critical objectives:
- Confirm your preclinical model: Is this the right species? The right size? Does the anatomy truly match your needs? Are you using the right numbers of test subjects: no more, no less? How do you know that?
- Refine your protocol: You'll discover practical challenges you never anticipated. Maybe the protocol calls for measurements every two hours, but in practice, four-hour intervals are the only feasible option. Better to discover this in a pilot than to rack up protocol deviations during your GLP study.
- Identify necessary endpoints: Pilot work helps you determine exactly what data you need (and what you don't). You might discover that weekly X-rays provide no useful information, or that additional blood work is essential for safety monitoring.
- Build confidence in your study design: GLP studies aren't for generating new insights. They are for proving, under regulatory scrutiny, that what you already know works is safe and reliable.
Without pilot work, you're essentially gambling with your GLP budget. Protocol deviations don't automatically invalidate a study, but when they start stacking up, they erode confidence in your data. Some deviations can even require complete study repeats.
Partner with Proven GLP Studies Excellence
At Veranex, our preclinical services team has supported more than 200 regulatory submissions, with the vast majority returned with minimal or no questions. Our Atlanta and Paris labs combine purpose-built GLP facilities with deep therapeutic area expertise across cardiovascular, neurology, orthopedics, ophthalmology, and regenerative medicine.
We don't just conduct studies. We help you build regulatory strategies that work. Our integrated approach means you have access to preclinical expertise, in-house histopathology, and regulatory guidance all under one roof, precisely when you need it.
If you're evaluating your readiness for GLP preclinical studies or need a partner who can guide you from pilot work through regulatory submission, contact our team today. Let's make sure you're truly ready before you invest.
